EDIT - Editas Medicine, Inc.

QQQ $ 623.55 $ 4.74 (0.77 %)

DIA $ 473.62 $ 1.85 (0.39 %)

SPY $ 681.61 $ 4.43 (0.65 %)

TLT $ 89.48 $ -0.01 (-0.01 %)

GLD $ 378.33 $ 2.38 (0.63 %)

Previous Close

$ 2.47

Open

$ 2.71

Bid

$ 2.50 x 2,200

Ask

$ 2.51 x 900

Day's Range

$ 2.48 - $ 2.71

52 Week Range

$ 0.91 - $ 4.54

Volume

3,157,362

Average Volume

Market Cap

222.1M

Beta (5Y Monthly)

$ 2.14

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2025	06-30-2025	10-Q
2	05-12-2025	03-31-2025	10-Q
3	03-05-2025	01-01-1970	10-K
4	11-04-2024	09-30-2024	10-Q
5	08-07-2024	06-30-2024	10-Q
6	05-08-2024	03-31-2024	10-Q
7	02-28-2024	12-31-2023	10-K
8	11-03-2023	09-30-2023	10-Q
9	08-02-2023	06-30-2023	10-Q
10	05-05-2023	03-31-2023	10-Q
11	02-22-2023	12-31-2022	10-K
12	11-02-2022	09-30-2022	10-Q
13	08-03-2022	06-30-2022	10-Q
14	05-04-2022	03-31-2022	10-Q
15	02-24-2022	12-31-2021	10-K
16	11-09-2021	09-30-2021	10-Q
17	08-05-2021	06-30-2021	10-Q
18	05-06-2021	03-31-2021	10-Q
19	02-26-2021	12-31-2020	10-K
20	11-06-2020	09-30-2020	10-Q
21	08-07-2020	06-30-2020	10-Q
22	05-08-2020	03-31-2020	10-Q
23	02-26-2020	12-31-2019	10-K
24	11-12-2019	09-30-2019	10-Q
25	08-07-2019	06-30-2019	10-Q
26	05-08-2019	03-31-2019	10-Q
27	03-01-2019	12-31-2018	10-K
28	11-08-2018	09-30-2018	10-Q
29	08-07-2018	06-30-2018	10-Q
30	05-04-2018	03-31-2018	10-Q
31	03-08-2018	12-31-2017	10-K
32	11-08-2017	09-30-2017	10-Q
33	08-09-2017	06-30-2017	10-Q
34	05-15-2017	03-31-2017	10-Q
35	03-03-2017	12-31-2016	10-K
36	11-09-2016	09-30-2016	10-Q
37	08-10-2016	06-30-2016	10-Q
38	05-13-2016	03-31-2016	10-Q
39	03-30-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Editas Medicine Q3 EPS $(0.28) Beats $(0.2...
11/10/2025 12:21:28

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.2...

Editas Medicine To Present Data On LDL Cho...
11/03/2025 14:10:07

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for seri...

intellia-freezes-key-trial-after-serious-liver-event-stock-tumbles

Intellia Freezes Key Trial After Serious L...
10/27/2025 14:38:29

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related advers...

Editas Medicine Reports In Vivo Preclinica...
10/09/2025 15:03:59

Editas Medicine To Deliver EDIT-401 Oral P...
10/06/2025 13:05:01

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serio...

my-top-biotech-stock-picks-and-portfolio-strategy-for-the-next-3-10-years

My Top Biotech Stock Picks And Portfolio S...
09/18/2025 17:10:48

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...

Editas Medicine Stock: A Deep Dive Into An...
09/05/2025 12:01:59

HC Wainwright & Co. Reiterates Buy on Edit...
09/05/2025 11:15:56

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Editas Medicine (NASDAQ:EDIT) with a Buy and maintains $5 pric...

Wells Fargo Maintains Equal-Weight on Edit...
09/03/2025 13:04:50

Wells Fargo analyst Yanan Zhu maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and raises the price target from $...

Editas Medicine Announces EDIT-401 As Lead...
09/02/2025 11:05:08

EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primatesEDIT-401 on track for human proof-of-concept ...

HC Wainwright & Co. Maintains Buy on Edita...
08/15/2025 11:23:02

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price t...

12 Health Care Stocks Moving In Wednesday'...
08/13/2025 17:06:22

Baird Maintains Outperform on Editas Medic...
08/13/2025 12:02:29

Baird analyst Joel Beatty maintains Editas Medicine (NASDAQ:EDIT) with a Outperform and raises the price target from $4 to $6.

Editas Medicine Q2 EPS $(0.63) Misses $(0....
08/12/2025 20:14:54

eli-lillys-13-billion-verve-deal-signals-confidence-in-gene-editing-space-analyst

Eli Lilly's $1.3 Billion Verve Deal Signal...
06/18/2025 17:59:21

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a...

Editas Medicine Reports 58% Mean HBG1/2 Pr...
06/12/2025 07:26:23

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically ...

12 Health Care Stocks Moving In Wednesday'...
05/21/2025 12:07:32

Editas Medicine Unveils New In Vivo Data H...
05/14/2025 11:07:14

Baird Maintains Outperform on Editas Medic...
05/13/2025 12:28:34

Baird analyst Joel Beatty maintains Editas Medicine (NASDAQ:EDIT) with a Outperform and lowers the price target from $8 to $4.

Editas Medicine Shares In Vivo Proof Of Co...
05/13/2025 11:06:33

In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associa...